Salivary cortisol is not associated with dexamethasone response in preterm infants with evolving bronchopulmonary dysplasia

期刊论文
发表日期：

2024年11月21日

查看全文

Tamorah Lewis,
Erik A. Jensen,
Sherry Courtney,
Jonathan Slaughter,
Matthew J. Kielt,
Narayan Prahbu Iyer,
Cheri Gauldin,
Christopher Nitkin,
Hung-Wen Yeh,
William Truog

摘要

Objective

Short-term treatment efficacy of systemic dexamethasone (DEX) in preterm infants with bronchopulmonary dysplasia (BPD) is highly variable. Our objective was to assess if salivary cortisol may serve as a reliable biomarker of steroid response.

Study design

Multi-site prospective observational cohort study. Salivary cortisol was measured before and after DEX treatment. Respiratory Severity Score (RSS) quantified clinical response.

Results

Fifty-four infants with median (inter-quartile range) gestational age of 25.1 (24.1,26.5) weeks initiated DEX at 30 (23,48) days’ postnatal age. Median baseline and post-treatment cortisol levels were 0.3 (0.2,0.6) μg/dl; 8.3 (5.5,16.5) nmol/L and 0.2 (0.1,0.3) μg/dl; 5.5 (2.8,8.3) nmol/L, respectively. RSS values decreased by a median of 3.1(1.6,5.0) Change in RSS did not correlate with baseline cortisol or change in cortisol levels.

Conclusion

In this first study to assess salivary cortisol as a biomarker for DEX response in BPD, salivary cortisol did not predict dexamethasone response.